1Name#
(1)This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 9) 2026.
(2)This instrument may also be cited as PB 118 of 2026.
2Commencement#
| Commencement information | ||
|---|---|---|
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 October 2026. | 1 October 2026 |
| 2. Schedule 1 | 1 October 2026. | 1 October 2026 |
(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
4Schedules#
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1 · Amendments commencing 1 October 2026
National Health (Minimum Stockholding) Determination 2023#
1 Schedule 1 (table)
Omit:
| Aciclovir | Tablet 200 mg | Oral | ARX-ACICLOVIR | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together |
| Aciclovir | Tablet 800 mg | Oral | ARX-ACICLOVIR | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together |
2 Schedule 1 (table)
Omit:
| Allopurinol | Tablet 100 mg | Oral | APO-ALLOPURINOL | 4 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together |
3 Schedule 1 (table)
Omit:
| Allopurinol | Tablet 300 mg | Oral | APO-ALLOPURINOL | 6 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together |
insert:
| Allopurinol | Tablet 300 mg | Oral | APO-ALLOPURINOL | 6 months stock by reference to usual demand |
4 Schedule 1 (table)
Omit:
| Allopurinol | Tablet 300 mg | Oral | NOUMED ALLOPURINOL | between 1 April 2026 to 30 September 2026—0 months stock by reference to usual demand |
5 Schedule 1 (table)
Omit:
| Amlodipine | Tablet 5 mg (as besilate) | Oral | APX-AMLODIPINE | 6 months stock by reference to usual demand of both Amlodipine APOTEX and APX-AMLODIPINE added together |
insert:
| Amlodipine | Tablet 5 mg (as besilate) | Oral | APX-AMLODIPINE | 6 months stock by reference to usual demand |
6 Schedule 1 (table)
Omit:
| Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Alphaclav Duo Viatris | after 31 December 2025—6 months stock by reference to usual demand of both Alphaclav Duo Viatris and AlphaClav Duo added together |
insert:
| Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Alphaclav Duo Viatris | 6 months stock by reference to usual demand |
7 Schedule 1 (table)
After:
| Aripiprazole | Tablet 10 mg | Oral | APO-Aripiprazole | 3 months stock by reference to usual demand |
insert:
| Aripiprazole | Tablet 10 mg | Oral | ARIPIPRAZOLE-WGR | Between 1 October 2026 and 28 February 2027—0 months stock by reference to usual demand |
8 Schedule 1 (table)
Omit:
| Atomoxetine | Capsule 100 mg (as hydrochloride) | Oral | Atomoxetine Sandoz | between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand |
9 Schedule 1 (table)
Omit:
| Bivalirudin | Powder for I.V. injection 250 mg (as trifluoroacetate) | Injection | BIVALIRUDIN ARX | 4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together |
10 Schedule 1 (table)
Omit:
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Bosentan Viatris | 4 months stock by reference to usual demand of both Bosentan Mylan and Bosentan Viatris added together |
11 Schedule 1 (table)
After:
| Captopril | Oral solution 5 mg per mL, 95 mL | Oral | Capoten | 4 months stock by reference to usual PBS demand |
insert:
| Cefalexin | Capsule 250 mg (as monohydrate) | Oral | Keflex | Between 1 October 2026 and 31 March 2027—0 months stock by reference to usual demand |
12 Schedule 1 (table)
Omit:
| Erlotinib | Tablet 150 mg (as hydrochloride) | Oral | Erlotinib APOTEX | after 30 November 2025—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
| Erlotinib | Tablet 150 mg (as hydrochloride) | Oral | ERLOTINIB ARX | after 30 November 2025—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
| Erlotinib | Tablet 25 mg (as hydrochloride) | Oral | Erlotinib APOTEX | 4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
| Erlotinib | Tablet 25 mg (as hydrochloride) | Oral | ERLOTINIB ARX | 4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
13 Schedule 1 (table)
Omit:
| Fluconazole | Capsule 200 mg | Oral | APO-Fluconazole | 4 months stock by reference to usual demand of both Fluconazole APOTEX and APO-Fluconazole added together |
14 Schedule 1 (table)
After:
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
insert:
| Glibenclamide | Tablet 5 mg | Oral | Daonil | Between 1 October 2026 and 31 May 2027—0 months stock by reference to usual demand |
15 Schedule 1 (table)
Omit:
| Glimepiride | Tablet 1 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
| Glimepiride | Tablet 2 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
| Glimepiride | Tablet 3 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
| Glimepiride | Tablet 4 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
insert:
| Glimepiride | Tablet 1 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand |
| Glimepiride | Tablet 2 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand |
| Glimepiride | Tablet 3 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand |
| Glimepiride | Tablet 4 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand |
16 Schedule 1 (table)
Omit:
| Hydrocortisone | Injection 100 mg (as sodium succinate) with 2 mL solvent | Injection | Solu-Cortef | 6 months stock by reference to usual PBS demand |
| Hydrocortisone | Injection 250 mg (as sodium succinate) with 2 mL solvent | Injection | Solu-Cortef | 6 months stock by reference to usual PBS demand |
17 Schedule 1 (table)
Omit:
| Imatinib | Capsule 100 mg (as mesilate) | Oral | ARX-IMATINIB | 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | ARX-IMATINIB | 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together |
insert:
| Imatinib | Capsule 100 mg (as mesilate) | Oral | ARX-IMATINIB | 3 months stock by reference to usual demand |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | ARX-IMATINIB | 3 months stock by reference to usual demand |
18 Schedule 1 (table)
Omit:
| Lamivudine | Tablet 150 mg | Oral | Lamivudine Viatris | after 30 September 2025—4 months stock by reference to usual demand of both Lamivudine Viatris and Lamivudine Alphapharm added together |
19 Schedule 1 (table)
Omit:
| Leflunomide | Tablet 10 mg | Oral | APO-LEFLUNOMIDE | 4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together |
| Leflunomide | Tablet 20 mg | Oral | APO-LEFLUNOMIDE | 4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together |
20 Schedule 1 (table)
Omit:
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | ARX-LERCANIDIPINE | 6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX-LERCANIDIPINE added together |
insert:
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | ARX-LERCANIDIPINE | 6 months stock by reference to usual demand |
21 Schedule 1 (table)
Omit:
| Letrozole | Tablet 2.5 mg | Oral | ARX-LETROZOLE | 4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together |
22 Schedule 1 (table)
Omit:
| Levetiracetam | Tablet 1 g | Oral | Levetiracetam Viatris | after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together |
23 Schedule 1 (table)
After:
| Levetiracetam | Tablet 1 g | Oral | LEVETIRACETAM-WGR | 6 months stock by reference to usual demand |
insert:
| Levetiracetam | Tablet 500 mg | Oral | Levetiracetam Viatris | 4 months stock by reference to usual demand of both Levetiracetam Mylan and Levetiracetam Viatris added together |
24 Schedule 1 (table)
Omit:
| Levetiracetam | Tablet 250 mg | Oral | Levetiracetam Viatris | after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together |
| Levetiracetam | Tablet 500 mg | Oral | Levetiracetam Mylan | between 1 July 2026 to 30 September 2026—0 months stock by reference to usual demand |
25 Schedule 1 (table)
Omit:
| Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electroylytes, 30 | Oral | Chemists’ Own Constipation Relief with Electrolytes | 4 months stock by reference to usual demand of both Chemists’ Own Macrogol with Electrolytes and Chemists’ Own Constipation Relief with Electrolytes added together |
26 Schedule 1 (table)
Omit:
| Modafinil | Tablet 100 mg | Oral | Modafinil Viatris | after 28 February 2025— 4 months stock by reference to usual demand of both Modafinil Viatris and Modafinil Mylan added together |
| Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | APX-Montelukast | 4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together |
| Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast Viatris | after 31 July 2025—4 months stock by reference to usual demand of both Montelukast Viatris and Montelukast Mylan added together |
| Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast Viatris | after 31 August 2025—4 months stock by reference to usual demand of both Montelukast Viatris and Montelukast Mylan added together |
| Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | ARX-MYCOPHENOLATE | 4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX-MYCOPHENOLATE added together |
27 Schedule 1 (table)
Omit:
| Naloxone | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | Injection | NARCAN | (a) between 1 July 2026 and 30 September 2026—560 packs of a pack quantity of 10(b) after 30 September 2026—4 months stock by reference to usual demand |
insert:
| Naloxone | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | Injection | NARCAN | 4 months stock by reference to usual demand |
28 Schedule 1 (table)
Omit:
| Octreotide | Injection 50 micrograms (as acetate) in 1 mL | Injection | Octreotide GH | between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand |
| Octreotide | Injection 50 micrograms (as acetate) in 1 mL | Injection | Octreotide (SUN) | between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand |
| Octreotide | Injection 50 micrograms (as acetate) in 1 mL | Injection | Sandostatin 0.05 | between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand |
| Octreotide | Injection 100 micrograms (as acetate) in 1 mL | Injection | Octreotide GH | between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand |
| Octreotide | Injection 100 micrograms (as acetate) in 1 mL | Injection | Octreotide (SUN) | between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand |
| Octreotide | Injection 100 micrograms (as acetate) in 1 mL | Injection | Sandostatin 0.1 | between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand |
29 Schedule 1 (table)
Omit:
| Olanzapine | Tablet 2.5 mg | Oral | APO-OLANZAPINE | 6 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together |
insert:
| Olanzapine | Tablet 2.5 mg | Oral | APO-OLANZAPINE | 6 months stock by reference to usual demand |
30 Schedule 1 (table)
Omit:
| Olanzapine | Tablet 5 mg | Oral | APO-OLANZAPINE | 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together |
31 Schedule 1 (table)
Omit:
| Olanzapine | Tablet 7.5 mg | Oral | APO-OLANZAPINE | 4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together |
32 Schedule 1 (table)
Omit:
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral | APO-OLMESARTAN/AMLODIPINE 20/5 | 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 20/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 20/5 mg added together |
33 Schedule 1 (table)
Omit:
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | APO-OLMESARTAN/AMLODIPINE 40/5 | 4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 40/5 mg added together |
34 Schedule 1 (table)
Omit:
| Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | Ondansetron ODT Viatris | after 30 September 2025—6 months stock by reference to usual demand of both Ondansetron ODT Viatris and Ondansetron Mylan ODT added together |
| Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | Ondansetron ODT Viatris | after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron ODT Viatris and Ondansetron Mylan ODT added together |
35 Schedule 1 (table)
Omit:
| Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | Ondansetron Tablets Viatris | after 31 May 2025—6 months stock by reference to usual demand of both Ondansetron Tablets Viatris and Ondansetron Mylan Tablets added together |
insert:
| Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | Ondansetron Tablets Viatris | 6 months stock by reference to usual demand |
36 Schedule 1 (table)
Omit:
| Ondansetron | Tablet 8 mg (as hydrochloride dihydrate) | Oral | Ondansetron Tablets Viatris | after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron Tablets Viatris and Ondansetron Mylan Tablets added together |
37 Schedule 1 (table)
Omit:
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APX-PANTOPRAZOLE | 6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together |
insert:
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APX-PANTOPRAZOLE | 6 months stock by reference to usual demand |
38 Schedule 1 (table)
Omit:
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APX-PANTOPRAZOLE | 6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together |
insert:
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APX-PANTOPRAZOLE | 6 months stock by reference to usual demand |
39 Schedule 1 (table)
After:
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | 5.5 months stock by reference to usual demand |
insert:
| Paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Poly Visc | Between 1 October 2026 and 28 February 2027—0 months stock by reference to usual demand |
40 Schedule 1 (table)
Omit:
| Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | ARX-PIOGLITAZONE | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |
41 Schedule 1 (table)
Omit:
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | APOTEX-Pioglitazone | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | ARX-PIOGLITAZONE | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | APOTEX-Pioglitazone | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | ARX-PIOGLITAZONE | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |
42 Schedule 1 (table)
Omit:
| Quetiapine | Tablet 100 mg (as fumarate) | Oral | APX-QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together |
| Quetiapine | Tablet 200 mg (as fumarate) | Oral | APX-QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together |
| Quetiapine | Tablet 25 mg (as fumarate) | Oral | APX-QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together |
| Quetiapine | Tablet 300 mg (as fumarate) | Oral | APX-QUETIAPINE | 4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together |
43 Schedule 1 (table)
Omit:
| Ramipril | Tablet 1.25 mg | Oral | Ramipril Viatris | (a) between 1 January 2025 and 28 February 2025—3 months stock by reference to usual demand of Tryzan Tabs 1.25(b) after 28 February 2025—3 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 1.25 added together |
insert:
| Ramipril | Tablet 1.25 mg | Oral | Ramipril Viatris | 3 months stock by reference to usual demand |
44 Schedule 1 (table)
Omit:
| Ramipril | Tablet 10 mg | Oral | Ramipril Viatris | after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 10 added together |
| Ramipril | Tablet 2.5 mg | Oral | Ramipril Viatris | after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 2.5 added together |
| Ramipril | Tablet 5 mg | Oral | Ramipril Viatris | after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 5 added together |
insert:
| Ramipril | Tablet 10 mg | Oral | Ramipril Viatris | 6 months stock by reference to usual demand |
| Ramipril | Tablet 2.5 mg | Oral | Ramipril Viatris | 6 months stock by reference to usual demand |
| Ramipril | Tablet 5 mg | Oral | Ramipril Viatris | 6 months stock by reference to usual demand |
45 Schedule 1 (table)
Omit:
| Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral | APO-RIZATRIPTAN ODT | 4 months stock by reference to usual demand of both Rizatriptan ODT APOTEX and APO-RIZATRIPTAN ODT added together |
46 Schedule 1 (table)
Omit:
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | APO-Rosuvastatin | 6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-Rosuvastatin added together |
| Rosuvastatin | Tablet 20 mg (as calcium) | Oral | APO-ROSUVASTATIN | 4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together |
| Rosuvastatin | Tablet 40 mg (as calcium) | Oral | APO-ROSUVASTATIN | 4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | APO-ROSUVASTATIN | 6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together |
insert:
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | APO-ROSUVASTATIN | 6 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | APO-ROSUVASTATIN | 6 months stock by reference to usual demand |
47 Schedule 1 (table)
Omit:
| Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30 | Inhalation | Salbutamol Cipla | between 1 April 2026 to 30 September 2026—0 months stock by reference to usual demand |
48 Schedule 1 (table)
Omit:
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral | ARX-SEVELAMER | 4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together |
49 Schedule 1 (table)
After:
| Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Sertraline generichealth | between 1 September 2026 to 31 December 2026—0 months stock by reference to usual demand |
insert:
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral | Sevelamer Lupin | between 1 October 2026 to 30 November 2026—0 months stock by reference to usual demand |
50 Schedule 1 (table)
Omit:
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Tenofovir ARX | 4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together |
51 Schedule 1 (table)
Omit:
| Vancomycin | Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together |
52 Schedule 1 (table)
Omit:
| Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together |
53 Schedule 1 (table)
Omit:
| Vincristine | I.V. injection containing vincristine sulfate 1 mg in 1 mL | Injection | DBL Vincristine Sulfate | between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand |
Sourced from the Federal Register of Legislation at legislation.gov.au, © Commonwealth of Australia, licensed under CC BY 4.0. Compilations may have been reformatted.